HLA-A*0201 | B2M | HPV16-E7

HLA-A*0201 | B2M | HPV16-E7

Produktanfrage

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
SoziniberceptOPT-302; VGX-300Phase 3 ClinicalOrphan Europe Sarl
Neovascularization, Pathologic; Retinal Diseases; Diabetic macular oedema; Retinal Degeneration; Eye Diseases; Macular Degeneration
Details
VEGF-C gene therapy (Herantis Pharma)LX-1101; Ad-VEGF-CPhase 2 ClinicalHerantis Pharma
Lymphedema
Details
IBI-333IBI-333Phase 1 ClinicalInnovent Biologics (Usa), Inc
Wet Macular Degeneration; Macular Degeneration
Details